Altimmune, Inc.ALTNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank79
3Y CAGR-2.0%
5Y CAGR+5.9%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-2.0%/yr
vs +39.8%/yr prior
5Y CAGR
+5.9%/yr
Recent deceleration
Acceleration
-41.8pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$66.43M-19.2%
2024$82.23M+25.0%
2023$65.80M-6.7%
2022$70.54M-5.4%
2021$74.54M+49.8%
2020$49.77M+180.2%
2019$17.77M-3.8%
2018$18.46M+0.3%
2017$18.41M+280.6%
2016$4.84M-